Proteoglycan aggrecan conducting T cell activation and apoptosis in a murine model of rheumatoid arthritis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Hanyecz, A ^a   Olasz, K ^a   Tarjanyi, O ^a   Nemeth, P ^a   Mikecz, K ^b   Glant, T T ^b   Boldizsar, F ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AGGRECAN; COLLAGEN TYPE 2; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 17; PROTEOGLYCAN; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

APOPTOSIS; ARTHRITIS; ARTICULAR CARTILAGE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARTILAGE; CYTOKINE PRODUCTION; EXPERIMENTAL ARTHRITIS; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEOGLYCAN INDUCED ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY;

AGGRECANS; ANIMALS; APOPTOSIS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; HUMANS; LYMPHOCYTE ACTIVATION; MICE; T-LYMPHOCYTES;

EID: 84896812551     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/942148     Document Type: Review

References (124)

1. Cs-Szabo G., Roughley P. J., Plaas A. H. K., Glant T. T., Large and small proteoglycans of osteoarthritic and rheumatoid articular cartilage. Arthritis and Rheumatism 1995 38 5 660 668 2-s2.0-0028921148
2. Glant T., Csongor J., Szücs T., Immunopathologic role of proteoglycan antigens in rheumatoid joint disease. Scandinavian Journal of Immunology 1980 11 3 247 252 2-s2.0-0018901050
3. Hardingham T. E., Muir H., Hyaluronic acid in cartilage and proteoglycan aggregation. Biochemical Journal 1974 139 3 565 581 2-s2.0-0016205359
4. Glant T. T., Buzás E. I., Finnegan A., Negroiu G., Cs-Szabó G., Mikecz K., Critical roles of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation. Journal of Immunology 1998 160 8 3812 3819 2-s2.0-0032522487
5. Walcz E., Deák F., Horváth P., Fülöp C., Doege K. J., Glant T. T., Complete coding sequence and deduced primary structure of mouse aggrecan. Transactions of the Annual Meeting 1993 18 656
6. Roughley P. J., The structure and function of cartilage proteoglycans. European Cells and Materials 2006 12 92 101 2-s2.0-33845407527
7. Fülöp C., Walcz E., Valyon M., Glant T. T., Expression of alternatively spliced epidermal growth factor-like domains in aggrecans of different species. Evidence for a novel module. Journal of Biological Chemistry 1993 268 23 17377 17383 2-s2.0-0027184489
8. Glant T. T., Finnegan A., Mikecz K., Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. Critical Reviews in Immunology 2003 23 3 199 250 2-s2.0-0141564778 10.1615/CritRevImmunol.v23.i3.20
9. Caterson B., Flannery C. R., Hughes C. E., Little C. B., Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biology 2000 19 4 333 344 2-s2.0-0034253761 10.1016/S0945-053X(00)00078-0
10. Arner E. C., Aggrecanase-mediated cartilage degradation. Current Opinion in Pharmacology 2002 2 3 322 329 2-s2.0-0036605643 10.1016/S1471-4892(02)00148-0
11. Bayliss M. T., Hutton S., Hayward J., Maciewicz R. A., Distribution of aggrecanase (ADAMts 4/5) cleavage products in normal and osteoarthritic human articular cartilage: the influence of age, topography and zone of tissue. Osteoarthritis and Cartilage 2001 9 6 553 560 2-s2.0-0034854048 10.1053/joca.2001.0425
12. Sandy J. D., Verscharen C., Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochemical Journal 2001 358 3 615 626 2-s2.0-0035884605 10.1042/0264-6021:3580615
13. Guerassimov A., Zhang Y., Banerjee S., Cartman A., Webber C., Esdaile J., Fitzcharles M.-A., Poole A. R., Autoimmunity to cartilage link protein in patients with rheumatoid arthritis and ankylosing spondylitis. Journal of Rheumatology 1998 25 8 1480 1484 2-s2.0-0031880751
14. Boldizsar F., Kis-Toth K., Tarjanyi O., Olasz K., Hegyi A., Mikecz K., Glant T. T., Impaired activation-induced cell death promotes spontaneous arthritis in antigen (cartilage proteoglycan)-specific T cell receptor-transgenic mice. Arthritis and Rheumatism 2010 62 10 2984 2994 2-s2.0-77957684725 10.1002/art.27614
15. Fosang A. J., Last K., Maciewicz R. A., Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. Journal of Clinical Investigation 1996 98 10 2292 2299 2-s2.0-0029852094
16. Olszewski J., McDonnell J., Stevens K., Visco D., Moore V., A matrix metalloproteinase-generated aggrecan neoepitope as a marker of skeletal maturation and aging in cartilage. Arthritis and Rheumatism 1996 39 7 1234 1237 2-s2.0-0029974815 10.1002/art.1780390724
17. Singer I. I., Kawka D. W., Bayne E. K., Donatelli S. A., Weidner J. R., Williams H. R., Ayala J. M., Mumford R. A., Lark M. W., Glant T. T., Nabozny G. H., David C. S., VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis. Journal of Clinical Investigation 1995 95 5 2178 2186 2-s2.0-0028937643
18. Hughes C. E., Caterson B., Fosang A. J., Roughley P. J., Mort J. S., Monoclonal antibodies that specifically recognize neoepitope sequences generated by "aggrecanase" and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. Biochemical Journal 1995 305 3 799 804 2-s2.0-0028919163
19. Poole A. R., Changes in the collagen and proteoglycan of articular cartilage in arthritis. Rheumatology 1986 10 316 371
20. Glant T. T., Mikecz K., Buzás E., Dayer E., Poole A. R., Kresina T., Anti-proteoglycan antibodies in experimental spondylitis. Monoclonal Antibodies, Cytokines, and Arthritis. Mediators of Inflammation and Therapy 1991 New York, NY, USA Marcel Dekker 341 356
21. Wegner N., Lundberg K., Kinloch A., Fisher B., Malmström V., Feldmann M., Venables P. J., Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunological Reviews 2010 233 1 34 54 2-s2.0-73249145617 10.1111/j.0105-2896.2009.00850.x
22. van Venrooij W. J., Pruijn G. J. M., Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Research 2000 2 4 249 251 2-s2.0-0034467062 10.1186/ar95
23. Alivernini S., Fedele A. L., Cuoghi I., Tolusso B., Ferracciolo G., Citrullination: the loss of tolerance and development of autoimmunity in rheumatoid arthritis. Reumatismo 2008 60 2 85 94 2-s2.0-55249084235
24. Schellekens G. A., de Jong B. A. W., van den Hoogen F. H. J., van de Putte L. B. A., van Venrooij W. J., Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. Journal of Clinical Investigation 1998 101 1 273 281 2-s2.0-0031974911
25. Bas S., Perneger T. V., Seitz M., Tiercy J.-M., Roux-Lombard P., Guerne P. A., Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology 2002 41 7 809 814 2-s2.0-0036316201
26. Taylor P., Gartemann J., Hsieh J., Creeden J., A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Diseases 2011 2011 815038 10.4061/2011/815038
27. Rantapää-Dahlqvist S., de Jong B. A. W., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W. J., Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism 2003 48 10 2741 2749 2-s2.0-18744430797 10.1002/art.11223
28. Aletaha D., Neogi T., Silman A. J., 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases 2010 69 10 1580 1588 2-s2.0-77957262195
29. Simon M., Girbal E., Sebbag M., Gomes-Daudrix V., Vincent C., Salama G., Serre G., The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies" autoantibodies specific for rheumatoid arthritis. Journal of Clinical Investigation 1993 92 3 1387 1393 2-s2.0-0027217907
30. Girbal-Neuhauser E., Durieux J.-J., Arnaud M., Dalbon P., Sebbag M., Vincent C., Simon M., Senshu T., Masson-Bessière C., Jolivet-Reynaud C., Jolivet M., Serre G., The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. Journal of Immunology 1999 162 1 585 594 2-s2.0-0032960781
31. Bizzaro N., Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine 2007 45 2 150 157 2-s2.0-33847121296 10.1515/CCLM.2007.027
32. Vander Cruyssen B., Cantaert T., Nogueira L., Clavel C., De Rycke L., Dendoven A., Sebag M., Deforce D., Vincent C., Elewaut D., Serre G., De Keyser F., Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Research and Therapy 2006 8 4, article R122 2-s2.0-70350554075 10.1186/ar2011
33. Snir O., Widhe M., Hermansson M., Von Spee C., Lindberg J., Hensen S., Lundberg K., Engström Å., Venables P. J. W., Toes R. E. M., Holmdahl R., Klareskog L., Malmström V., Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis and Rheumatism 2010 62 1 44 52 2-s2.0-74849107568 10.1002/art.25036
34. Qin X., Deng Y., Xu J., Li T.-J., Li S., Zhao J.-M., Meta-analysis: diagnostic value of serum anti-mutated citrullinated vimentin antibodies in patients with rheumatoid arthritis. Rheumatology International 2011 31 6 785 794 2-s2.0-79959961587 10.1007/s00296-009-1343-3
35. Bartoloni E., Alunno A., Bistoni O., Bizzaro N., Migliorini P., Morozzi G., Doria A., Mathieu A., Lotzniker M., Allegri F., Riccieri V., Alpini C., Gabrielli A., Tampoia M., Gerli R., Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmunity Reviews 2012 11 815 820 2-s2.0-84858711544 10.1016/j.autrev.2012.02.015
36. Kuna A. T., Mutated citrullinated vimentin antibodies in rheumatoid arthritis. Clinica Chimica Acta 2012 413 1-2 66 73 2-s2.0-82955220304 10.1016/j.cca.2011.10.020
37. Mathsson L., Mullazehi M., Wick M. C., Sjöberg O., Van Vollenhoven R., Klareskog L., Rönnelid J., Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis and Rheumatism 2008 58 1 36 45 2-s2.0-38149026334 10.1002/art.23188
38. Cook A. D., Gray R., Ramshaw J., Mackay I. R., Rowley M. J., Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Research & Therapy 2004 6 5 R477 R483 2-s2.0-20744458153
39. Koivula M.-K., Åman S., Karjalainen A., Hakala M., Risteli J., Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? Annals of the Rheumatic Diseases 2005 64 10 1443 1450 2-s2.0-27744595134 10.1136/ard.2004. 031211
40. Koivula M.-K., Savolainen E., Kaipiainen-Seppänen O., Kautiainen H., Luosujärvi R., Hakala M., Risteli J., Sensitivity and specificity of autoantibodies binding to citrullinated carboxyterminal telopeptides of types I and II collagens in an early arthritis series. Rheumatology 2008 47 5 656 659 2-s2.0-42949087389 10.1093/rheumatology/ken092
41. Uysal H., Nandakumar K. S., Kessel C., Haag S., Carlsen S., Burkhardt H., Holmdahl R., Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunological Reviews 2010 233 1 9 33 2-s2.0-73249142493 10.1111/j.0105-2896.2009.00853.x
42. Uysal H., Bockermann R., Nandakumar K. S., Sehnert B., Bajtner E., Engström Å., Serre G., Burkhardt H., Thunnissen M. M. G. M., Holmdahl R., Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. Journal of Experimental Medicine 2009 206 2 449 462 2-s2.0-63049101247 10.1084/jem.20081862
43. Snir O., Widhe M., Von Spee C., Lindberg J., Padyukov L., Lundberg K., Engström Å., Venables P. J., Lundeberg J., Holmdahl R., Klareskog L., Malmström V., Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Annals of the Rheumatic Diseases 2009 68 5 736 743 2-s2.0-66149124137 10.1136/ard.2008.091355
44. Lundberg K., Kinloch A., Fisher B. A., Wegner N., Wait R., Charles P., Mikuls T. R., Venables P. J., Antibodies to citrullinated α -enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis and Rheumatism 2008 58 10 3009 3019 2-s2.0-54949091137 10.1002/art.23936
45. Anzilotti C., Merlini G., Pratesi F., Tommasi C., Chimenti D., Migliorini P., Antibodies to viral citrullinated peptide in rheumatoid arthritis. Journal of Rheumatology 2006 33 4 647 651 2-s2.0-33645823916
46. Pratesi F., Tommasi C., Anzilotti C., Chimenti D., Migliorini P., Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis and Rheumatism 2006 54 3 733 741 2-s2.0-33644926954 10.1002/art.21629
47. Mahdi H., Fisher B. A., Källberg H., Plant D., Malmström V., Rönnelid J., Charles P., Ding B., Alfredsson L., Padyukov L., Symmons D. P. M., Venables P. J., Klareskog L., Lundberg K., Specific interaction between genotype, smoking and autoimmunity to citrullinated α -enolase in the etiology of rheumatoid arthritis. Nature Genetics 2009 41 12 1319 1324 2-s2.0-70649108632 10.1038/ng.480
48. Nielen M. M. J., van Schaardenburg D., Reesink H. W., Twisk J. W. R., van de Stadt R. J., van der Horst-Bruinsma I. E., de Koning M. H. M. T., Habibuw M. R., Dijkmans B. A. C., Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 4 535 537 2-s2.0-33645127251 10.1136/ard.2005.040659
49. van de Stadt L. A., de Koning M. H. M. T., van de Stadt R. J., Wolbink G., Dijkmans B. A. C., Hamann D., van Schaardenburg D., Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis and Rheumatism 2011 63 11 3226 3233 2-s2.0-80155127957 10.1002/art.30537
50. Mikecz K., Glant T. T., Buzas E., Poole A. R., Cartilage proteoglycans as potential autoantigens in humans and in experimental animals. Agents and Actions 1988 23 1-2 63 66 2-s2.0-0023915760
51. Glant T. T., Mikecz K., Thonar EJMA, Kuettner K. E., Woessner J. F., Howell D. S., Immune responses to cartilage proteoglycans in inflammatory animal models and human diseases. Cartilage Degradation: Basic and Clinical Aspects 1992 New York, NY, USA Marcel Dekker 435 473
52. Glant T. T., Fulop C., Mikecz K., Buzas E., Molnar G., Erhardt P., Proteoglycan-specific autoreactive antibodies and T-lymphocytes in experimental arthritis and human rheumatoid joint diseases. Biochemical Society Transactions 1990 18 5 796 799 2-s2.0-0025185815
53. Herman J. H., Wiltse D. W., Dennis M. V., Immunopathologic significance of cartilage antigenic components in rheumatoid arthritis. Arthritis and Rheumatism 1973 16 3 287 297 2-s2.0-0015903237
54. Golds E. E., Stephen I. B. M., Esdaile J. M., Lymphocyte transformation to connective tissue antigens in adult and juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, and a nonarthritic control population. Cellular Immunology 1983 82 1 196 209 2-s2.0-0021059608
55. Karopoulos C., Rowley M. J., Ilic M. Z., Handley C. J., Presence of antibodies to native G1 domain of aggrecan core protein in synovial fluids from patients with various joint diseases. Arthritis and Rheumatism 1996 39 12 1990 1997 2-s2.0-0030447192 10.1002/art.1780391207
56. Guerassimov A., Zhang Y. P., Banerjee S., Cellular immunity to the G1 domain of cartilage proteoglycan aggrecan is enhanced in patients with rheumatoid arthritis but only after removal of keratan sulfate. Arthritis and Rheumatism 1998 41 1019 1025
57. Zou J., Zhang Y., Thiel A., Rudwaleit M., Shi S.-L., Radbruch A., Poole R., Braun J., Sieper J., Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. Rheumatology 2003 42 7 846 855 2-s2.0-0041411251 10.1093/rheumatology/keg230
58. von Delwig A., Locke J., Robinson J. H., Ng W.-F., Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis and Rheumatism 2010 62 1 143 149 2-s2.0-74849112402 10.1002/art.25064
59. Witter J., Roughley P. J., Webber C., The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis and Rheumatism 1987 30 5 519 529 2-s2.0-0023269417
60. Holoshitz J., The rheumatoid arthritis HLA-DRB1 shared epitope. Current Opinion in Rheumatology 2010 22 3 293 298 2-s2.0-77950195997 10.1097/BOR.0b013e328336ba63
61. Stuart J. M., Townes A. S., Kang A. H., The role of collagen autoimmunity in animal models and human diseases. Journal of Investigative Dermatology 1982 79 1 1215 1275 2-s2.0-0019996631
62. Besenyei T., Kadar A., Tryniszewska B., Non-MHC risk alleles in rheumatoid arthritis and in the syntenic chromosome regions of corresponding animal models. Clinical and Developmental Immunology 2012 2012 284751
63. Glant T. T., Mikecz K., Arzoumanian A., Poole A. R., Proteoglycan-induced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis and Rheumatism 1987 30 2 201 212 2-s2.0-0023254937
64. Trentham D. E., Townes A. S., Kang A. H., Autoimmunity to type II collagen: an experimental model of arthritis. Journal of Experimental Medicine 1977 146 3 857 868 2-s2.0-0017657009
65. Courtenay J. S., Dallman M. J., Dayan A. D., Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980 283 5748 666 668 2-s2.0-0018830639
66. Mikecz K., Glant T. T., Poole A. R., Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthritis and Rheumatism 1987 30 3 306 318 2-s2.0-0023197152
67. Trentham D. E., Townes A. S., Kang A. H., David J. R., Humoral and cellular sensitivity to collagen in type II collagen induced arthritis in rats. Journal of Clinical Investigation 1978 61 1 89 96 2-s2.0-0017874061
68. Glant T. T., Bardos T., Vermes C., Variations in susceptibility to proteoglycan-induced arthritis and spondylitis among C3H substrains of mice. Evidence of genetically acquired resistance to autoimmune disease. Arthritis and Rheumatism 2001 44 682 692
69. Glant T. T., Cs-Szabó G., Nagase H., Jacobs J. J., Mikecz K., Progressive polyarthritis induced in BALB/c mice by aggrecan from human osteoarthritic cartilage. Arthritis and Rheumatism 1998 41 1007 1018
70. Farkas B., Boldizsar F., Tarjanyi O., Laszlo A., Lin S. M., Hutas G., Tryniszewska B., Mangold A., Nagyeri G., Rosenzweig H. L., Finnegan A., Mikecz K., Glant T. T., BALB/c mice genetically susceptible to proteoglycan-induced arthritis and spondylitis show colony-dependent differences in disease penetrance. Arthritis Research and Therapy 2009 11 1, article R21 2-s2.0-62149099615 10.1186/ar2613
71. Adarichev V. A., Bárdos T., Christodoulou S., Phillips M. T., Mikecz K., Glant T. T., Major histocompatibility complex controls susceptibility and dominant inheritance, but not the severity of the disease in mouse models of rheumatoid arthritis. Immunogenetics 2002 54 3 184 192 2-s2.0-0036089570 10.1007/s00251-002-0462-8
72. Otto J. M., Cs-Szabó G., Gallagher J., Identification of multiple loci linked to inflammation and autoantibody production by a genome scan of a murine model of rheumatoid arthritis. Arthritis and Rheumatism 1999 42 2524 2531
73. Otto J. M., Mikecz K., Finnegan A., A genome scan in a murine model of rheumatoid arthritis localizes loci associated with different traits and genetic backgrounds. Arthritis and Rheumatism 1999 42, article S233
74. Mikecz K., Glant T. T., Buzas E., Poole A. R., Proteoglycan-induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c mice. Arthritis and Rheumatism 1990 33 6 866 876 2-s2.0-0025306842 10.1002/art.1780330614
75. + T cells. Cellular Immunology 1992 144 2 347 357 2-s2.0-0026446525 10.1016/0008-8749(92)90250-S
76. Finnegan A., Mikecz K., Tao P., Glant T. T., Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. Journal of Immunology 1999 163 10 5383 5390 2-s2.0-0033571645
77. Nakae S., Nambu A., Sudo K., Iwakura Y., Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice. Journal of Immunology 2003 171 11 6173 6177 2-s2.0-0344585384
78. Lubberts E., Joosten L. A. B., Oppers B., Van den Bersselaar L., Coenen-De Roo C. J. J., Kolls J. K., Schwarzenberger P., Van de Loo F. A. J., Van den Berg W. B., IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. Journal of Immunology 2001 167 2 1004 1013 2-s2.0-0035879192
79. Koenders M. I., Kolls J. K., Oppers-Walgreen B., Van Den Bersselaar L., Joosten L. A. B., Schurr J. R., Schwarzenberger P., Van Den Berg W. B., Lubberts E., Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis and Rheumatism 2005 52 10 3239 3247 2-s2.0-26844554064 10.1002/art.21342
80. Boldizsar F., Tarjanyi O., Nemeth P., Mikecz K., Glant T. T., Th1/Th17 polarization and acquisition of an arthritogenic phenotype in arthritis-susceptible BALB/c, but not in MHC-matched, arthritis-resistant DBA/2 mice. International Immunology 2009 21 5 511 522 2-s2.0-65549089043 10.1093/intimm/dxp018
81. Doodes P. D., Cao Y., Hamel K. M., Wang Y., Farkas B., Iwakura Y., Finnegan A., Development of proteoglycan-induced arthritis is independent of IL-17. Journal of Immunology 2008 181 1 329 337 2-s2.0-47949090745
82. Doodes P. D., Cao Y., Hamel K. M., Wang Y., Rodeghero R. L., Mikecz K., Glant T. T., Iwakura Y., Finnegan A., IFN- γ regulates the requirement for IL-17 in proteoglycan-induced arthritis. Journal of Immunology 2010 184 3 1552 1559 2-s2.0-77949314815 10.4049/jimmunol.0902907
83. Yoo T. J., Kim S.-Y., Stuart J. M., Floyd R. A., Olson G. A., Cremer M. A., Kang A. H., Induction of arthritis in monkeys by immunization with type II collagen. Journal of Experimental Medicine 1988 168 2 777 782 2-s2.0-0023720232
84. Holmdahl R., Jansson L., Gullberg D., Rubin K., Forsberg P. O., Klareskog L., Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II. Clinical and Experimental Immunology 1985 62 3 639 646 2-s2.0-0022213707
85. Larsson P., Kleinau S., Holmdahl R., Klareskog L., Homologous type II collagen-induced arthritis in rats. Characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis and Rheumatism 1990 33 5 693 701 2-s2.0-0025280812 10.1002/art.1780330512
86. Luross J. A., Williams N. A., The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001 103 4 407 416 2-s2.0-0034888885 10.1046/j.1365-2567.2001.01267.x
87. Terato K., Hasty K. A., Reife R. A., Cremer M. A., Kang A. H., Stuart J. M., Induction of arthritis with monoclonal antibodies to collagen. Journal of Immunology 1992 148 7 2103 2108 2-s2.0-0026600294
88. Ortmann R. A., Shevach E. M., Susceptibility to collagen-induced arthritis: cytokine-mediated regulation. Clinical Immunology 2001 98 1 109 118 2-s2.0-0035182141 10.1006/clim.2000.4961
89. Vermeire K., Heremans H., Vandeputte M., Huang S., Billiau A., Matthys P., Accelerated collagen-induced arthritis in IFN- γ receptor-deficient mice. Journal of Immunology 1997 158 11 5507 5513 2-s2.0-0031156936
90. Boissier M.-C., Chiocchia G., Bessis N., Hajnal J., Garotta G., Nicoletti F., Fournier C., Biphasic effect of interferon- γ in murine collagen-induced arthritis. European Journal of Immunology 1995 25 5 1184 1190 2-s2.0-0028979121 10.1002/eji.1830250508
91. Chu C.-Q., Swart D., Alcorn D., Tocker J., Elkon K. B., Interferon- γ regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis and Rheumatism 2007 56 4 1145 1151 2-s2.0-34247247352 10.1002/art.22453
92. Cook A. D., Rowley M. J., Mackay I. R., Gough A., Emery P., Antibodies to type II collagen in early rheumatoid arthritis: correlation with disease progression. Arthritis and Rheumatism 1996 39 10 1720 1727 2-s2.0-0029782998
93. Morgan K., Clague R. B., Collins I., Ayad S., Phinn S. D., Holt P. J. L., A longitudinal study of anticollagen antibodies in patients with rheumatoid arthritis. Arthritis and Rheumatism 1989 32 2 139 145 2-s2.0-0024533129
94. Buzás E. I., Végvári A., Murad Y. M., Finnegan A., Mikecz K., Glant T. T., T-cell recognition of differentially tolerated epitopes of cartilage proteoglycan aggrecan in arthritis. Cellular Immunology 2005 235 2 98 108 2-s2.0-27644558109 10.1016/j.cellimm.2004.08.006
95. Buzas E. I., Brennan F. R., Mikecz K., Garzo M., Negroiu G., Hollo K., Cs-Szabo G., Pintye E., Glant T. T., A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. Journal of Immunology 1995 155 5 2679 2687 2-s2.0-0029051908
96. Buzás E. I., Hanyecz A., Murad Y., Hudecz F., Rajnavölgyi E., Mikecz K., Glant T. T., Differential recognition of altered peptide ligands distinguishes two functionally discordant (arthritogenic and nonarthritogenic) autoreactive T cell hybridoma clones. Journal of Immunology 2003 171 6 3025 3033 2-s2.0-0042333432
97. Fülöp C., Cs-Szabó G., Glant T. T., Species-specific alternative splicing of the epidermal growth factor-like domain 1 of cartilage aggrecan. Biochemical Journal 1996 319 3 935 940 2-s2.0-0029854326
98. Lohmander L. S., Neame P. J., Sandy J. D., The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis and Rheumatism 1993 36 9 1214 1222 2-s2.0-0027445981 10.1002/art.1780360906
99. Dudhia J., Davidson C. M., Wells T. M., Vynios D. H., Hardingham T. E., Bayliss M. T., Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage. Biochemical Journal 1996 313 3 933 940 2-s2.0-0030069604
100. Hanyecz A., Bárdos T., Berlo S. E., Buzás E., Nesterovitch A. B., Mikecz K., Glant T. T., Induction of arthritis in SCID mice by T cells specific for the "shared epitope" sequence in the G3 domain of human cartilage proteoglycan. Arthritis and Rheumatism 2003 48 10 2959 2973 2-s2.0-0141733607 10.1002/art.11275
101. Gregersen P. K., Silver J., Winchester R. J., The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis and Rheumatism 1987 30 11 1205 1213 2-s2.0-0023500817
102. Albani S., Tuckwell J. E., Esparza L., Carson D. A., Roudier J., The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule. Journal of Clinical Investigation 1992 89 1 327 331 2-s2.0-0026503670
103. Albani S., Ravelli A., Massa M., De Benedetti F., Andree G., Roudier J., Martini A., Carson D. A., Immune responses to the Escherichia coli dnaJ heat shock protein in juvenile rheumatoid arthritis and their correlation with disease activity. Journal of Pediatrics 1994 124 4 561 565 2-s2.0-0028231446
104. Albani S., Keystone E. C., Nelson J. L., Ollier W. E. R., La Cava A., Montemayor A. C., Weber D. A., Montecucco C., Martini A., Carson D. A., Positive selection in autoimmunity: abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Medicine 1995 1 5 448 452 2-s2.0-0029078361
105. Albani S., Carson D. A., A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. Immunology Today 1996 17 10 466 470 2-s2.0-0030271825 10.1016/0167-5699(96)20029-G
106. O'Neill S. K., Shlomchik M. J., Glant T. T., Cao Y., Doodes P. D., Finnegan A., Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. Journal of Immunology 2005 174 6 3781 3788 2-s2.0-14844347864
107. Szántó S., Bárdos T., Szabó Z., David C. S., Buzás E. I., Mikecz K., Glant T. T., Induction of arthritis in HLA-DR4-humanized and HLA-DQ8-humanized mice by human cartilage proteoglycan aggrecan but only in the presence of an appropriate (Non-MHC) genetic background. Arthritis and Rheumatism 2004 50 6 1984 1995 2-s2.0-2642582570 10.1002/art.20285
108. Brennan F. R., Negroiu G., Buzas E. I., Fulop C., Hollo K., Mikecz K., Glant T. T., Presentation of cartilage proteoglycan to a T cell hybridoma derived from mouse with proteoglycan induced arthritis. Clinical and Experimental Immunology 1995 100 1 104 110 2-s2.0-0028913104
109. Mikecz K., Glant T. T., Migration and homing of lymphocytes to lymphoid and synovial tissues in proteoglycan-induced murine arthritis. Arthritis and Rheumatism 1994 37 9 1395 1403 2-s2.0-0028154805 10.1002/art.1780370919
110. Law S. C., Street S., Yu C. H., T-cell autoreactivity to citrullinated autoantigenic peptides in rheumatoid arthritis patients carrying HLA-DRB1 shared epitope alleles. Arthritis Research and Therapy 2012 14, article R118
111. Glant T. T., Radacs M., Nagyeri G., Olasz K., Laszlo A., Boldizsar F., Hegyi A., Finnegan A., Mikecz K., Proteoglycan-induced arthritis and recombinant human proteoglycan aggrecan G1 domain-induced arthritis in BALB/c mice resembling two subtypes of rheumatoid arthritis. Arthritis and Rheumatism 2011 63 5 1312 1321 2-s2.0-79955569160 10.1002/art.30261
112. Smith-Garvin J. E., Koretzky G. A., Jordan M. S., T cell activation. Annual Review of Immunology 2009 27 591 619 2-s2.0-67650752137 10.1146/annurev.immunol.021908.132706
113. Berlo S. E., Guichelaar T., Ten Brink C. B., Van Kooten P. J., Hauet-Broeren F., Ludanyi K., Van Eden W., Broeren C. P., Glant T. T., Increased arthritis susceptibility in cartilage proteoglycan-specific T cell receptor-transgenic mice. Arthritis and Rheumatism 2006 54 8 2423 2433 2-s2.0-33746983501 10.1002/art.22013
114. Olasz K., Boldizsar F., Kis-Toth K., Tarjanyi O., Hegyi A., van Eden W., Rauch T. A., Mikecz K., Glant T. T., T cell receptor (TCR) signal strength controls arthritis severity in proteoglycan-specific TCR transgenic mice. Clinical and Experimental Immunology 2012 167 2 346 355 2-s2.0-84855802194 10.1111/j.1365-2249.2011.04506.x
115. O'Neill S. K., Cao Y., Hamel K. M., Doodes P. D., Hutas G., Finnegan A., Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. Journal of Immunology 2007 179 8 5109 5116 2-s2.0-38449115303
116. O'Neill S. K., Glant T. T., Finnegan A., The role of B cells in animal models of rheumatoid arthritis. Frontiers in Bioscience 2007 12 5 1722 1736 2-s2.0-34249799584 10.2741/2184
117. Linterman M. A., Rigby R. J., Wong R. K., Yu D., Brink R., Cannons J. L., Schwartzberg P. L., Cook M. C., Walters G. D., Vinuesa C. G., Follicular helper T cells are required for systemic autoimmunity. Journal of Experimental Medicine 2009 206 3 561 576 2-s2.0-63449096041 10.1084/jem.20081886
118. Wilson E. H., Zaph C., Mohrs M., Welcher A., Siu J., Artis D., Hunter C. A., B7RP-1-ICOS interactions are required for optimal infection-induced expansion of CD4+ Th1 and Th2 responses. Journal of Immunology 2006 177 4 2365 2372 2-s2.0-33746891247
119. Frey O., Meisel J., Hutloff A., Bonhagen K., Bruns L., Kroczek R. A., Morawietz L., Kamradt T., Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis. Annals of the Rheumatic Diseases 2010 69 8 1495 1501 2-s2.0-77955458613 10.1136/ard.2009.119164
120. Frey O., Reichel A., Bonhagen K., Morawietz L., Rauchhaus U., Kamradt T., Regulatory T cells control the transition from acute into chronic inflammation in glucose-6-phosphate isomerase-induced arthritis. Annals of the Rheumatic Diseases 2010 69 8 1511 1518 2-s2.0-77955462438 10.1136/ard.2009.123422
121. Kim Y. O., Kim H. J., Kim S. K., Chung J.-H., Hong S.-J., Association of the CD28/CTLA4/ICOS polymorphisms with susceptibility to rheumatoid arthritis. Clinical Chemistry and Laboratory Medicine 2010 48 3 345 353 2-s2.0-77249124540 10.1515/CCLM.2010.074
122. Iannone F., Lapadula G., The inhibitor of costimulation of T cells: abatacept. Journal of Rheumatology 2012 89 supplement 100 102
123. Zhang J., Xu X., Liu Y., Activation-induced cell death in T cells and autoimmunity. Cellular and Molecular Immunology 2004 186 192
124. Singh K., Deshpande P., Pryshchep S., Colmegna I., Liarski V., Weyand C. M., Goronzy J. J., ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. Journal of Immunology 2009 183 12 8258 8267 2-s2.0-76249124674 10.4049/jimmunol.0901784